Biblio
C
Xu C, Huang KKyon, Law JHao, Chua JShijia, Sheng T, Flores NM, Pizzi MPool, Okabe A, Tan ALay Keng, Zhu F, et al. Comprehensive molecular phenotyping of -deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Gut. 2023.
G
Xing M, Ooi WFong, Tan J, Qamra A, Lee P-H, Li Z, Xu C, Padmanabhan N, Lim JQuan, Guo YAmanda, et al. Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. J Clin Invest. 2020.
R
Ho SWei Ting, Sheng T, Xing M, Ooi WFong, Xu C, Sundar R, Huang KKyon, Li Z, Kumar V, Ramnarayanan K, et al. Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities. Gut. 2022.